Wakabayashi & Daimon cardiometabolic index as an indicator to assess risk in adults. A systematic review / Índice cardiometabólico de Wakabayashi y Daimon como indicador para evaluar el riesgo en adultos. Una revisión sistemática

Objective To analyze the Wakabayashi & Daimon (2015) equation, as a predictive indicator of cardiometabolic diseases and its comparison with other indices. Design A systematic review was carried out between January and March 2023, according to the PRISMA statement. Data source Scopus, Web of Science, and PubMed databases were reviewed using “cardiometabolic index” (CMI) as the search term. Study selection The following inclusion criteria were determined: studies in adults with cardiometabolic diseases using the Wakabayashi & Daimon (2015) CMI formula in different populations; studies that validate or compare the equation or that demonstrate the effects of the intervention. Data extraction Of the 11 selected articles, the characteristics of the population, type of study, indicators for the validation of the CMI, the reported statistics and the conclusions that were recorded in a comparative table were obtained. Results and conclusions Odds ratio, hazard ratio, sensitivity, and specificity were used to assess associations, risk, effectiveness, and validity of the tests, indicating favorable relationships between the factors analyzed and the results obtained. Validation and probabilistic analysis of the CMI were performed against diverse diseases such as obesity [Man >60y=AUC=0.90 (0.75–1.00) (p=0.01), Se=100, Sp=81.8, YI=0.82 and OR 4.66 and Women >60y=AUC=0.95 (0.88–1.00), p=0.001, Se=90.0, Sp=100, YI=0.90 and OR=36.27]; cardiovascular diseases [AUC=0.617, Se=0.675, Sp=0.509; HR=1.48 (1.33, 1.65), p=<0.001], among others. In conclusion CMI is a new utility index that broadly identifies the presence of risk that leads to cardiometabolic diseases in adults. (AU)

Objetivo Analizar la ecuación de Wakabayashi et al. del 2015 como indicador de predicción de enfermedades cardiometabólicas y su comparación con otros índices.Diseño Se realizó una revisión sistemática entre enero y marzo del 2023, de acuerdo con la declaración PRISMA. Fuente de datos Se revisaron las bases de datos Scopus, Web of Science y PubMed utilizando «índice cardiometabólico» (ICM) como término de búsqueda. Selección de los estudios Se determinaron los siguientes criterios de inclusión: estudios en adultos con enfermedades cardiometabólicas que utilizaron la fórmula ICM de Wakabayashi et al. en diferentes poblaciones; que validaran o compararan la ecuación o que demostraran los efectos de la intervención. Extracción de datos De los 11 artículos seleccionados, se obtuvieron las características de la población, tipo de estudio, indicadores para la validación del ICM, la estadística reportada y las conclusiones que se registraron en una tabla comparativa. Resultados y conclusiones Para evaluar las asociaciones, el riesgo, la efectividad y la validez de las pruebas se utilizaron odds ratio (OR), hazard ratio (HR), sensibilidad y especificidad, indicando relaciones favorables entre los factores analizados y los resultados obtenidos. La validación y el análisis probabilístico del ICM se realizaron frente a diversas enfermedades como obesidad (hombres >60 años=AUC=0,90 [0,75-1,00], [p=0,01], Se=100, Sp=81,8, YI=0,82 y OR 4,66; y mujeres >60 años=AUC=0,95 [0,88-1,00], p=0,001, Se=90,0, Sp=100, YI=0,90 y OR=36,27); enfermedades cardiovasculares (AUC=0,617, Se=0,675, Sp=0,509; HR=1,48 [1,33, 1,65] p≤0,001), entre otros. En conclusión, el ICM es un nuevo índice de utilidad que identifica ampliamente la presencia de riesgo para conducir a enfermedades cardiometabólicas en adultos. (AU)

Dislipemia y circunferencia de cuello en pacientes de un hospital privado peruano / Dyslipidemia and neck circumference in patients from a Peruvian private hospital

Introducción: Las dislipidemias son alteraciones que están asociadas al riesgo de enfermedades cardiovasculares, infarto agudo de miocardio, evento cerebrovascular (ECV) o la artropatía periférica.Objetivo: Analizar la relación entre la circunferencia de cuello y el perfil lipídico de pacientes adultos atendidos en la clínica privada Rebagliatti.Materiales y métodos: Investigación de enfoque cuantitativo de diseño no experimental, transversal de nivel correlacional – causal. La muestra del estudio estuvo conformada por 120 pacientes ambulatorios de 18 a 59 años que asistieron a clínica privada Rebagliatti, durante el periodo octubre a noviembre del 2023. La medición de la circunferencia de cuello se realizó con una cinta métrica de la marca Lufkin y los valores del perfil lipídico se obtuvieron de la revisión de la historia clínica del paciente. Para evaluar la relación de las variables se utilizó la prueba no paramétrica coeficiente de correlación de Spearman.Resultados: el promedio de la circunferencia de cuello fue 36,21 ± 2,34 cm, del colesterol total fue 237,55 ± 67,47 mg/dL, del colesterol LDL fue 126,55 ± 34,97 mg/dL, del colesterol HDL fue 37,10 ± 4,35 mg/dL y de los triglicéridos fue 219,72 ± 88,65 mg/dL. Al analizar la relación entre la circunferencia de cuello y el nivel de perfil lipídico se encontró (p<0,05).Conclusiones: La circunferencia de cuello tiene relación directa con el nivel de colesterol total, triglicéridos y colesterol LDL; no obstante, se encontró una relación inversa con el nivel de colesterol HDL en pacientes.(AU)

Introduction: Dyslipidemias are alterations that are asso-ciated with the risk of cardiovascular diseases, acute myocar-dial infarction, and cerebral vascular disease (CVD).Objective: To analyze the relationship between dyslipide-mia and neck circumference in patients treated in a privatehospital in Peru.Materials and methods: Quantitative research with anon-experimental, cross-sectional design at a correlational –causal level, carried out on 120 patients aged 18-59 who at-tended the Los Andes private clinic in November 2023; loca-ted in the city of Huancayo – Peru. The measurement of neckcircumference was performed with a Lufkin brand measuringtape and the lipid profile through low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TotalChol) and triglycerides (TG), was obtained from the patient’smedical history. A descriptive analysis was performed (mean,standard deviation, minimum, maximum); To evaluate the re-lationship of the variables, the non-parametric Spearman co-rrelation coefficient test was used.Results: the average neck circumference was 36.21 ± 2.34 cm, total cholesterol was 237.55 ± 67.47 mg/dL,LDL cholesterol was 126.55 ± 34.97 mg/dL, HDL choleste-rol was 37.10 ± 4.35 mg/dL and triglycerides was 219.72 ± 88.65 mg/dL. When analyzing the relationship betweenneck circumference with total cholesterol, triglycerides andLDL, a direct and significant relationship was obtained(p<0.05). However, when evaluating the relationship withHDL cholesterol, an inverse and significant relationship wasobtained (p<0.05).Conclusions: Patients with a larger neck circumferencehave a higher risk of dyslipidemia. Likewise, a direct and sig-nificant relationship was found with the level of total choles-terol, triglycerides and LDL cholesterol; however, inverse rela-tionship with the level of HDL cholesterol. Therefore, neckcircumference measurement represents a useful and practicalmethod in predicting dyslipidemia.(AU)

Correlation of Plasma and Salivary Osteocalcin Levels with Nascent Metabolic Syndrome Components with and Without Pre/Diabetes Biochemical Parameters / Correlación de los niveles de osteocalcina en plasma y saliva con los componentes del síndrome metabólico naciente con y sin parámetros bioquímicos de prediabetes

Objectives: This study aimed to compare and correlate plasma and salivary levels of cardiometabolic risk biomarkers’ of pharmacotherapy (appraised using colorimetric assays), adiposity, and atherogenicity indices. Methods: 61 Nascent MetS subjects vs. 30 lean normoglycemic and healthy controls were recruited in Family Medicine outpatient clinics/Jordan University Hospital (a referral medical center). Fasting blood and saliva specimens were collected. Clinical and anthropometric variables were determined along with atherogenecity and adiposity indices. Results: Among nascent MetS (metabolic syndrome) recruits, almost half were normoglycemic, 43% were prediabetic and 8% were diabetic. Pronouncedly Glycemic (FPG and Alc) and lipid parameters (TG, HDL-C and non-HDL-C), adiposity indices (BMI, WHR, WtHR, Conicity-index, BAI, LAP, VAI) and atherogenicity indices (AIP, TC/HDL-C, LDL-C/HDL-C, non-HDL-C/HDL-C and TG/HDL-C) were higher in the nascent MetS group (P<0.05 vs. controls). Markedly among the plasma cardiometabolic risk biomarkers (P<0.05 vs. controls) in the nascent MetS group, adipolin, cathepsin S, ghrelin, irisin, LBP, leptin, and osteocalcin were higher but plasma FGF1 levels were oddly lower. Significantly (P<0.05 vs. controls) nascent MetS –linked salivary levels of adipolin and LBP were higher as opposed to the lower cathepsin S. Only osteocalcin, amongst 9 metabolic risk biomarkers studied, had remarkably significant correlation between plasma and saliva levels, in both total sample and MetS patients (P<0.05). Markedly in the nascent MetS only group, both plasma and salivary osteocalcin correlated with FPG and A1c (P<0.05); salivary osteocalcin correlated with BMI and LAP (P<0.05). Likewise, in the total sample plasma osteocalcin correlated significantly with BMI, BAI, WHt R, SBP, DBP, TG, LAP, VAI, TG/HDL-C and AIP (P<0.05), while salivary osteocalcin had substantial correlations only with FPG and A1c (P<0.05). Conclusion: Association of nascent MetS-related plasma and salivary osteocalcin levels and clinical characteristics and indices propagate salivary osteocalcin as a non-invasive marker for clinical control of MetS-/preDM.(AU)

Metabolic syndrome in systemic lupus erythematosus patients under Mediterranean diet / Síndrome metabólico en pacientes con lupus eritematoso sistémico con patrón de dieta mediterránea

Background and aims: Metabolic syndrome (MetS) is a chronic proinflammatory and prothrombotic condition that exacerbates insulin resistance, oxidative damage, and cardiovascular risk, being more prevalent in patients with systemic lupus erythematosus (SLE), a chronic multisystemic autoimmune disorder. This study aim was to determine the prevalence of MetS and associations with SLE clinical characteristics, cardiovascular risk and dietary pattern in a population of Spanish SLE patients. Design and methods: Cross-sectional study of 293 patients was conducted (90.4% females; mean age 46.8 (12.94)). The diagnosis of MetS was established based on the criteria of the National Cholesterol Education Program Adult Treatment Panel III. SLE Disease Activity Index (SLEDAI-2K) and SDI Damage Index were used to assess disease activity and disease-related damage, respectively. Med Diet adherence was assessed through a 14 items questionnaire on food consumption frequency and habits. Results: MetS was present in 15% SLE patients. Triglycerides, high-density lipoprotein cholesterol, systolic blood pressure and waist circumference were significantly increased (p<0.001) in the group of MetS patients. Patients with MetS showed significantly increased SDI damage index (1.70 (1.69) vs 0.88 (1.12), p<0.001) and complement C3 level (118.70 (32.67) vs 107.55 (26.82), p=0.011). No significant differences were observed according to Med Diet adherence level. Conclusion: We observed a lower prevalence of MetS in SLE than that reported in previous studies, which may be a result of the good level of adherence to the MedDiet in our study sample. Additionally, MetS was associated with higher SDI and complement C3 levels but no with medication use.(AU)

Antecedentes y objetivos: El síndrome metabólico (SM) es una condición crónica proinflamatoria y protrombótica que exacerba resistencia a insulina, daño oxidativo y riesgo cardiovascular, más prevalente en pacientes con lupus eritematoso sistémico (LES) y trastorno autoinmune multisistémico crónico. El objetivo del estudio fue determinar la prevalencia de SM y asociación con características clínicas del LES, riesgo cardiovascular y patrón dietético en pacientes españoles con LES. Diseño y métodos: Estudio transversal, 293 pacientes (90,4% mujeres; edad media 46,85 [12,94]). Diagnóstico de SM según criterios National Cholesterol Education Program Adult Treatment Panel III. Se utilizó el Índice de Actividad de la Enfermedad del LES (SLEDAI-2K) e Índice de Daño del LES para evaluar actividad de la enfermedad y el daño relacionado con la enfermedad. Adherencia a la dieta mediterránea (DM) se evaluó mediante un cuestionario de 14 ítems sobre frecuencia y hábitos de consumo de alimentos. Resultados: El 15% de los pacientes con LES presentaron SM. Encontramos triglicéridos, colesterol de lipoproteínas de alta densidad, presión arterial sistólica y perímetro cintura significativamente elevados (p<0,001) en pacientes con SM. Pacientes con SM mostraron índice de daño SDI (1,70 [1,69] vs. 0,88 [1,12]; p<0,001) y nivel de complemento C3 (118,70 [32,67] vs. 107,55 [26,82]; p=0,011) significativamente elevados. No diferencias significativas según el nivel de adherencia a la DM. Conclusiones: Observamos menor prevalencia de SM en pacientes con LES que la descrita en estudios previos, podría deberse a la buena adherencia a la DM en nuestra muestra. El SM se asoció con mayores niveles de SDI y complemento C3, no con el uso de medicación.(AU)

Limitaciones y oportunidades para la adopción de la dieta mediterránea en adultos chilenos con elementos diagnósticos del síndrome metabólico / Limitations and opportunities for the appropriation of the Mediterranean diet in Chilean adults with diagnostic elements of metabolic syndrome

Antecedentes: un estilo de alimentación saludable, específicamente la dieta mediterránea (DMed), es un factor asociado a bajo riesgo, menorprevalencia y mejor manejo de las enfermedades crónicas. Sin embargo, existe información limitada respecto a cómo los pacientes incorporanpropuestas de este patrón alimentario en su vida cotidiana.Objetivo: identificar factores y condiciones que pueden influir en la adherencia a la DMed en Chile.Métodos: estudio cualitativo exploratorio en 17 pacientes de ambos sexos de entre 35 y 65 años que presentaban algún criterio diagnósticode síndrome metabólico (SMet). Mediante entrevistas en profundidad y grupos focales se indagaron el conocimiento, la valoración, las actitudesy las prácticas asociadas a cambios y mantenimiento de alimentación con énfasis en la DMed. El análisis de la información se realizó bajo elenfoque de teoría fundada usando el softwar e ATLAS.ti.Resultados: los participantes reconocieron el valor de una alimentación saludable tipo DMed, pero declararon bajo conocimiento (identificaciónde algunos alimentos aislados) de ella, junto con facilitadores (variedad de ingredientes) y limitantes (sabor, disponibilidad/costo de algunosalimentos) para su adopción rutinaria. Además, el cambio de hábitos alimentarios genera alta carga cognitiva y emocional inicial que requiereesfuerzo no solo individual sino también relacional, pues implica modificaciones de prácticas familiares y colectivas.Conclusiones: la información obtenida sobre barreras y oportunidades para adherir a una alimentación saludable como la DMed resulta clavepara diseñar e implementar intervenciones nutricionales basadas en este patrón alimentario y que puedan ser sostenibles en el tiempo para elenfrentamiento de las enfermedades crónicas en Chile.(AU)

Background: a healthy food intake pattern, specifically the Mediterranean diet (MedDiet), is a factor associated with reduced risk, lowerprevalence, and better management of chronic diseases. However, there is limited information regarding how patients integrate proposals foradherence to this food pattern in their daily lives.Objective: to identify factors and conditions that influence adherence to the MedDiet in Chile.Methods: an exploratory qualitative study was applied in 35 to 65-year-old patients of both sexes who presented at least one diagnostic criterionof metabolic syndrome (MetS). Through in-depth interviews and focal groups, knowledge, assessment, attitudes, and practices associated withchanges and maintenance of healthy eating habits, with emphasis on the MedDiet, were investigated. Information analysis was carried out underthe grounded theory approach using the ATLAS.ti software.Results: participants recognized the value of healthy eating, including the MedDiet, but declared low knowledge (identification of single foodsitems) together with facilitators (variety of ingredients) and limiting factors (taste, availability/cost of some items, family dynamics) for its routineadoption. In addition, change in eating habits generates a high initial cognitive and emotional load that requires not only individual but alsorelational effort as it implies modifications of family and collective practices.Conclusions: information obtained on barriers and opportunities to adhere to healthy eating such as the MedDiet is key to design and implementnutritional interventions based on this food pattern and that can be sustainable in time for chronic disease management in Chile.(AU)

Consumo de fructosa y síndrome metabólico en pacientes adultos de un Hospital Militar / Fructose consumption and metabolic syndrome in adult patients of a military hospital

Introducción: La fructosa de la dieta se metaboliza a nivel hepático, en donde estimula la fructólisis, la glucólisis, la lipogénesis y la producción de glucosa, esto conlleva a la dislipidemia mixta, hiperglucemia e hígado graso; aumentando el riesgo de síndrome metabólico.Objetivo: Determinar la asociación entre el consumo de fructosa y síndrome metabólico en pacientes adultos atendidos en el Hospital Militar Central “Coronel Luis Arias Schreiber”.Materiales y Métodos: Investigación de enfoque cuantitativo, diseño no experimental, transversal, correlacional-causal. La población de estudio estuvo conformada por 75 pacientes adultos. Se incluyó pacientes mayores de 18 años de edad; quienes en forma voluntaria firmaron el consentimiento informado y presentaron registros actualizados de perfil bioquímico, fueron excluidos pacientes con discapacidad mental, motora y/o física. Los valores de presión arterial y perfil bioquímico; se obtuvo de las historias clínicas y la valoración antropométrica a través de la medición del peso corporal, talla y circunferencia abdominal; la ingesta de fructosa se obtuvo a través de un cuestionario de frecuencia de consumo semicuantitativo. Se utilizó la prueba estadística de Chi cuadrado para evaluar la asociación de variables.Resultados: El 61,3% presentó Síndrome Metabólico (SM), el 88% presentan un inadecuado consumo de fructosa (>25g/día). El índice de masa corporal (IMC) promedio fue de 30,34 (DE ±4,0); el nivel de glucosa en ayunas fue 100,13 mg/dL (DE ±11,25). Al asociar el consumo inadecuado de fructosa con el Síndrome Metabólico, se obtuvo un valor p= 0,010 (p<0,05). Asimismo, el consumo inadecuado de fructosa añadida tuvo asociación con el SM (p<0,05). No obstante, al asociar ingesta de fructosa natural con el SM, se obtuvo p =0.466 (p>0,05).(AU)

Introduction: Dietary fructose is metabolized in the liver,where it stimulates fructolysis, glycolysis, lipogenesis andglucose production, which leads to mixed dyslipidemia, hy-perglycemia and fatty liver; increasing the risk of metabolicsyndrome. Objetive: Determine the association between fructose con-sumption and metabolic syndrome in adult patients treated atthe “Coronel Luis Arias Schreiber” Central Military Hospital. Materials and methods: A quantitative approach studywas carried out, with a non-experimental, cross-sectional andcorrelational-causal design. The study population consisted of 75 adult patients. Patients over 18 years of age were in-cluded; who voluntarily signed the informed consent and pre-sented updated biochemical profile records. Patients withmental, motor and/or physical disabilities were excluded.Blood pressure and biochemical profile values were obtainedfrom medical records and anthropometric assessmentthrough measurement of body weight, height, and abdominalcircumference. Fructose intake was obtained through a semi-quantitative consumption frequency questionnaire. The Chisquare statistical test was used to evaluate the association ofvariables. Results: 61.3% presented Metabolic Syndrome (MS), 88%presented inadequate fructose consumption (>25g/day). Theaverage body mass index (BMI) was 30.34 (SD ±4.0); Thefasting glucose level was 100.13 mg/dL (SD ±11.25). Whenassociating inadequate fructose consumption with MetabolicSyndrome, a p value = 0.010 (p < 0.05) was obtained.Likewise, inadequate consumption of added fructose was as-sociated with MS (p<0.05). However, when associating natu-ral fructose intake with MS, p =0.466 (p>0.05) was obtained.Conclusions. A high consumption of added fructose in in-dustrialized foods has a greater association with the develop-ment of Metabolic Syndrome; It is necessary to reduce thefructose content in industrialized foods.(AU)

Liraglutide for the treatment of obesity among patients with hidradenitis suppurativaLiraglutida en el tratamiento de la obesidad en pacientes con hidradenitis supurativa / Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa Liraglutida en el tratamiento de la obesidad en pacientes con hidradenitis supurativa

Background and aims: Hidradenitis suppurativa (HS) is associated with obesity. Weight loss is frequently reflected in an amelioration in the severity of the lesions. Case reports have suggested that liraglutide might improve not only weight but also skin. We aimed to study the effects of liraglutide 3mg in patients with obesity and HS on metabolic and dermatological parameters. Methods: 14 patients started treatment with liraglutide for 3 months. Severity of the lesions was evaluated using the Hurley Staging System and quality of life with the DLQI (Dermatology Quality Index). Results: There was a significant reduction in BMI (39.3±6.2 vs 35.6±5.8; p=0.002), waist circumference (121.3±19.2 vs 110.6±18.1cm; p=0.01), CRP (4.5±2.2 vs 3±2.1mg/L; p=0.04), homocysteine (16.2±2.9 vs 13.3±3μmol/L; p=0.005) and plasma cortisol (15.9±4.8 vs 12.6±4.5μg/dL; p=0.007). Hurley (2.6±0.5 vs 1.1±0.3; p=0.002) and DLQI (12.3±2.8 vs 9.7±6.9; p=0.04) improved significantly. In multiple regression analysis, weight loss did not correlate with any inflammatory parameter or Hurley. Conclusions: Liraglutide 3mg is effective and safe among patients with HS and obesity. Long-term studies are mandatory to assess the effects of liraglutide on skin lesions and inflammatory markers among subjects with HS beyond weight loss.(AU)

Antecedentes y objetivos: La hidradenitis supurativa (HS) se asocia a la obesidad. La pérdida de peso frecuentemente comporta una mejora en la gravedad de las lesiones. Casos aislados han sugerido que la liraglutida podría mejorar no solo el peso sino también la piel. Nuestro objetivo fue estudiar los efectos de liraglutida 3mg en pacientes con obesidad y HS sobre los parámetros metabólicos y dermatológicos. Métodos: Catorce pacientes iniciaron tratamiento con liraglutida durante 3meses. La gravedad de las lesiones se evaluó mediante la Escala de Hurley y la calidad de vida con el Dermatology Quality Index (DLQI). Resultados: Hubo una reducción significativa en el IMC (39,3±6,2 vs 35,6±5,8; p=0,002), la circunferencia de cintura (121,3±19,2 vs 110,6±18,1cm; p=0,01), la PCR (4,5±2,2 vs 3±2,1mg/l; p=0,04), la homocisteína (16,2±2,9 vs 13,3±3μmol/l; p=0,005) y el cortisol plasmático (15,9±4,8 vs 12,6±4,5μg/dl; p=0,007). El Hurley (2,6±0,5 vs 1,1±0,3; p=0,002) y la DLQI (12,3±2,8 vs 9,7±6,9; p=0,04) mejoraron significativamente. En el análisis de regresión múltiple, la pérdida de peso no se correlacionó con ningún parámetro inflamatorio ni con el Hurley. Conclusiones: Liraglutida 3mg es eficaz y segura en pacientes con HS y obesidad. Serán necesarios estudios a largo plazo para evaluar los efectos de la liraglutida sobre las lesiones cutáneas y los marcadores inflamatorios en la HS más allá de la pérdida de peso.(AU)

Trends and seasonality of information searches, carried out through Google, on metabolic syndrome and occupational health: infodemiological study

Objetivo: Este estudio tuvo como objetivo analizar y relacionar el interés de la población, a través de tendencias de búsqueda de información, sobre el Síndrome Metabólico (MS) con la Salud Laboral (OH).Método: Estudio ecológico y correlacional del Volumen Relativo de Búsqueda (RSV) obtenido de la consulta de Google Trends, segmentado en 3 períodos buscados relacionados con la antigüedad; fecha de consulta: 30 de sep-tiembre de 2023.Resultados: La media más baja del RSV fue para el tema MS (2,23 ± 0,87), aunque hubo una correlación positiva en el RSV entre MS y OH (R = 0,56; p < 0,05). Se observó asociación (p < 0,05) entre los 3 períodos estudiados, excepto para los temas Hipertensión y Obesidad Central, pero significativamente menor en el período actual para los Temas MS y OH. Se encontró una estacionalidad moderada en el tema MS (KPSS = 0,14; p > 0,05), y se demostraron diferen-cias significativas en la búsqueda de información entre países desarrollados y no desarrollados (p > 0,05).Conclusiones: A través de sus búsquedas de información, toda la población demostró tener un menor conocimien-to sobre la MS que sobre las enfermedades que la componen. Se encontró relación entre las búsquedas de infor-mación realizadas sobre MS y OH. El estudio de las tendencias de búsqueda de información puede proporcionar información útil sobre el interés de la población por los datos de enfermedades, así como permitiría gradualmente analizar diferencias en popularidad, o interés incluso entre distintos países. (AU)

Objective: This study aimed to analyse and relate the population interest through information search trends, on Metabolic Syndrome (MS) with the Occupational Health (OH).Method: Ecological and correlational study of the Relative Search Volume (RSV) obtained from Google Trends que-ry, segmented into 3 searched periods concerning antiquity; date of query: September 30, 2023.Results: The lowest mean of the RSV was for the MS Topic (2.23 ± 0.87), albeit there was a positive correlation in the RSV amid MS and OH (R = 0.56; p < 0.05). Association (p < 0.05) was observed between the 3 periods under study, except for the Hypertension and Central Obesity topics, but significantly lower in the current period for the MS and OH Topics. Moderate seasonality was found in the MS topic (KPSS = 0.14; p > 0.05), and significant differences were demonstrated in the information search between developed and undeveloped countries (p > 0.05).Conclusions: Through their information searches, the whole population showed to have a dearth of knowledge of MS than of its component diseases. A relationship was found between the information searches carried out on MS and OH. The study of information search trends may provide useful information on the population’s interest in the disease data, as well as would gradually allow the analysis of differences in popularity, or interest even between different countries. (AU)

Association between the genetic variant in the vitamin D pathway (rs2282679), circulating 25-hydroxyvitamin D levels, insulin resistance and metabolic syndrome criteria / Asociación entre la variante genética en la vía de la vitamina D (rs2282679), niveles circulantes de 25-hidroxivitamina D, resistencia a la insulina y criterios de síndrome metabólico

Background and aims: some studies have reported links between 25-hydroxyvitamin D levels and the presence of metabolic syndrome. The aim of the present study was to evaluate whether an association exists among 25-hydroxyvitamin D, rs2282679 of the GC gene and metabolic syndrome (MS). Methods: the study involved a population of 134 postmenopausal obese females. Measurements of anthropometric parameters, blood pressure, bone turnover markers, fasting blood glucose, insulin resistance (HOMA-IR), lipid profile, C-reactive protein and prevalence of MS were recorded. Genotype of CG gene polymorphism (rs2282679) was evaluated. Results: insulin (delta: 4.6 ± 0.9 mUI/l; p = 0.02), triglycerides (delta: 21.6 ± 2.9 mg/dl; p = 0.04) and HOMA-IR (delta: 1.1 ± 0.9 unit; p = 0.02) were lower in TT subjects than TG + GG patients. The percentages of individuals who had MS (OR = 2.80, 95 % CI = 1.39-5.65; p = 0.02), hypertriglyceridemia (OR = 2.39, 95 % CI = 1.44-5.96; p = 0.01), and hyperglycemia (OR = 2.72, 95 % CI = 1.23-6.00; p = 0.43) were higher in G allele carriers. Logistic regression analysis showed an increased risk of MS in G allele carriers (OR = 2.36, 95 % CI = 1.11-5.91, p = 0.02) and an increased risk of 25-hydroxyvitamin D deficiency (< 20 ng/ml) (OR = 2.43, 95 % CI = 1.13-6.69, p = 0.02), too. Conclusions: a negative association among G allele and insulin resistance, hypertriglyceridemia, deficiency of 25 hydroxyvitamin D levels and MS was reported in this population. (AU)

Antecedentes y objetivos: algunos estudios han demostrado una relación entre los niveles de 25-hidroxivitamina D y la presencia del síndrome metabólico. El objetivo de este estudio fue evaluar si existe una asociación entre la 25-hidroxivitamina D, la variante rs2282679 del gen GC y el síndrome metabólico (SM). Métodos: el estudio involucró a una población de 134 mujeres obesas posmenopáusicas. Se registraron parámetros antropométricos, presión arterial, marcadores de recambio óseo, glucemia en ayunas, resistencia a la insulina (HOMA-IR), perfil lipídico, proteína C reactiva y prevalencia de SM. Se evaluó el genotipo del polimorfismo del gen CG (rs2282679). Resultados: los niveles de insulina (delta: 4,6 ± 0,9 mUI/l; p = 0.02), triglicéridos (delta: 21,6 ± 2,9 mg/dl; p = 0,04) y HOMA-IR (delta: 1,1 ± 0,9 unidades; p = 0,02) fueron menores en los sujetos TT que en los pacientes TG + GG. Los porcentajes de individuos que tenían SM (OR = 2,80, IC 95 % = 1,39-5,65; p = 0,02), hipertrigliceridemia (OR = 2,39, IC 95 % = 1,44-5,96; p = 0,01) e hiperglucemia (OR = 2,72, IC 95 % = 1,23-6,00; p = 0,43) fueron mayores en los portadores del alelo G. El análisis de regresión logística mostró un mayor riesgo de SM en los portadores del alelo G (OR = 2,36, IC 95 % = 1,11-5,91; p = 0,02) y un mayor riesgo de deficiencia de 25-hidroxivitamina D (< 20 ng/ml) (OR = 2,43, IC 95 % = 1,13-6,69; p = 0,02). Conclusiones: en esta población hemos detectado una asociación negativa entre el alelo G y la resistencia a la insulina, hipertrigliceridemia, deficiencia niveles de 25-hidroxivitamina D y SM. (AU)

Estilo de vida y síndrome metabólico en el personal de salud de un hospital, 2022 / Lifestyle and metabolic syndrome in hospital health personnel, 2022

Fundamentos: El síndrome metabólico es un conjunto de factores de riesgo cardiovascular que junto con unestilo de vida inadecuado puede generar una importante morbimortalidad en la población adulta, afectandosu salud y productividad. El objetivo fue determinar la relación entre el estilo de vida y el síndromemetabólico (SM) en el personal de la salud durante la pandemia por COVID-19 en un hospital en el distrito deAte, 2022.Métodos: Diseño no experimental, descriptivo, correlacional y transversal. Los participantes fueron 416trabajadores de un hospital en el distrito de Ate. El SM fue valorado según la definición la FederaciónInternacional de Diabetes (FID) y el estilo de vida mediante el cuestionario Fantástico. Para la asociación devariables se aplicó prueba de chi-cuadrado.Resultados: Participaron 304 (73,1%) mujeres y 112 (26,9%) hombres, con edades entre 30-59 años (n=395,94,9%) y mayores de 60 años (n=21, 5,1%). La prevalencia del SM fue del 52,2%. Se observó una relaciónentre estilos de vida y el SM. Al identificarse las características clínicas del personal de salud se encontrósegún los componentes del SM diferenciado por género, en mujeres y varones que además de presentarObesidad central, HTA, triglicéridos elevados y glicemia alterada.Conclusiones: La prevalencia de SM se presentó en más de la mitad de los participantes, siendo superior enlas mujeres; se encontró asociación entre la presencia de SM y los estilos de vida.(AU)

Background: The metabolic syndrome is a set of cardiovascular risk factors that together with an inadequatelifestyle can generate significant morbidity and mortality in the adult population, affecting their health andproductivity. The objective was to determine the relationship between lifestyle and metabolic syndrome (MS)in health personnel during the COVID-19 pandemic in a hospital in Ate district, 2022.Methods: Non-experimental, descriptive, correlational and cross-sectional design. The participants were 416workers from a hospital in Ate district. MS was assessed according to the definition of the InternationalDiabetes Federation (IDF) and lifestyle using the Fantastic questionnaire. For the association of variables, achi-square test was applied.Results: 304 (73.1%) women and 112 (26.9%) men participated, aged between 30-59 years (n=395, 94.9%)and over 60 years old (n=21, 5.1%). The prevalence of MS was 52.2%. A relationship was observed betweenlifestyles and MS. When the clinical characteristics of the health personnel were identified, it was foundaccording to the components of the MS differentiated by gender, in women and men who, in addition topresenting central obesity, HBP, elevated triglycerides and altered glycemia.Conclusions: The prevalence of MS was present in more than half of the participants, being higher in women;an association was found between the presence of MS and lifestyles.(AU)

Neck circumference as an indicator of Obesity for MetabolicSyndrome in Mexican Healthcare workers

Background: Neck circumference (NC) is a novel anthropometric indicator to assess adiposity in the cervical regionthat is rarely used in Mexico. The greatest advantage of this evaluation is the saving of time, minimal use of instruments, and no pre requisites for patients. Objective: This study aimed to determine the effective-ness of NC as an indicator of obesity for Metabolic Syndrome(MetS) in comparison with BMI and Waist Circumference(WC), and to define NC cutoff levels based on parameters established by the International Diabetes Federation in a groupof healthcare workers from a Public Health Hospital of the State of Morelos, Mexico. Methods: This was a no-randomized, cross-sectional-observational study. Instruments: Anthropometric evaluation and biochemical parameters: lipid profile, fasting glucose, and blood pressure. Statistical analysis: Descriptive, correlational, Poisson multiple regression adjusted by age/sex, and ROC curves using SPSS.23 program. Results: 200 healthcare workers were recruited (146 women and 54 men), age ẋ=42.87, σ=11.25 years. The prevalence of metS was 38% (37% in women and 40.7% in men). BMI, WC, and NC were significantly correlated: BMI and WC (r=.924),BMI and NC (r=.814), and NC and WC (r=.810) (p=.01).Like wise, they were related to hyperglycemia, hypertriglyceridemia, hypertension, and decreased in HDL-cholesterol levels. The NC best cut-off points coupled with two or more components of MetS in women was ≥35.12 cm [AUC=0.765 (95%CI, 0.688-0.843)] and in men ≥41.25 cm [AUC=0.787 (95%CI, 0.688-0.906)]. Conclusion: NC proved to be a reliable indicator that can be quickly and inexpensively evaluated for the determination of obesity for the preliminary diagnosis of MetS (AU)

Prevalence and risk factors of anxiety symptoms in first-episode and drug-naïve major depressive disorder patients with metabolic syndrome

Background and objectives Patients with major depressive disorder (MDD) have high comorbidity with metabolic syndrome (MetS), although anxiety is prevalent comorbidity in MDD patients. However, there is no study on anxiety symptoms (AS) in MDD patients with MetS. Therefore, we aimed to identify the prevalence and risk factors of AS in patients with MetS who experienced a first-episode and drug naïve (FEDN) of MDD. Methods In this cross-sectional study, 1718 FEDN of MDD outpatients with MetS were included. Sociodemographic data, clinical characteristics, suicidal attempts, and physical and biochemical parameters were collected. Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD), and Positive and Negative Syndrome Scale (PANSS) positive subscale were performed to detect the AS. Multiple linear regression analysis was used to analyze the correlation. Results The prevalence of AS in MDD patients with MetS was 85.96%, which was 1.79 times greater than that in patients with MDD alone (P<0.05). MDD patients with MetS had a greater rate of attempted suicide, a higher HAMD total score, and a higher diastolic blood pressure than MDD patients without AS (P<0.05). Their combination could distinguish AS in MDD patients. Moreover, HAMD score, thyroid-stimulating hormone (TSH) levels, PANSS positive score, and suicide attempts were related to HAMA scores in MDD patients with comorbid MetS (P<0.05). Conclusion There is a significant frequency of AS in MDD patients with MetS. Multiple clinical indicators and metabolic markers are associated with AS in patients with MDD and MetS. (AU)

Características clínicas y metabólicas en adultos con diabetes tipo 2 según la presencia de criterios diagnósticos de síndrome metabólico / Clinical and metabolic characteristics in adults with Type 2 diabetes according to the presence of diagnostic criteria for metabolic syndrome

Objetivo: determinar las características clínicas y metabólicas en adultos con diabetes tipo 2 según la presencia de criterios diagnósticos de síndrome metabólico (SM).Método: estudio descriptivo transversal con muestreo probabilístico aleatorio simple que incluyó a 49 pacientes con diabetes tipo 2. Se midió composición corporal, presión arterial y parámetros bioquímicos. Para determinar el diagnóstico de SM se aplicaron los criterios de la Federación Internacional de Diabetes. Se realizó análisis bivariante entre quienes presentaron criterios diagnósticos de SM y quienes no, utilizándose la prueba de contraste de hipótesis U de Mann Whitney.Resultados: la edad media de la muestra estudiada fue de 59,7 (DE: 11,5 años). La mayoría de los participantes fue mujer (65,3%) y con nivel socioeconómico medio (75,5%). La prevalencia de SM fue del 40% y la hiperglicemia fue la alteración más frecuente (93,3%). La mayoría de los pacientes con SM mostró, de manera estadísticamente significativa (p< 0,05), sobrepeso y obesidad, así como cifras más altas de índice de masa corporal, circunferencia de cintura, colesterol total, triglicéridos, glucosa, índices aterogénicos y tensión arterial.Conclusiones: los pacientes con DMT2 mostraron una alta prevalencia de SM. En los pacientes con SM, la hiperglicemia fue la alteración más frecuente, seguida de obesidad central medida por la circunferencia de cintura, y de acuerdo con su IMC, la mayoría presentó sobrepeso y obesidad. La media de triglicéridos, tensión arterial e índices aterogénicos fueron mayores en comparación con quienes no cumplían criterios diagnósticos de SM. (AU)

Objective: to determine the clinical and metabolic characteristics in adults with Type 2 diabetes according to the presence of diagnostic criteria for metabolic syndrome (MS).Method: a descriptive cross-sectional study with simple randomized probability sampling, including patients with Type 2 diabetes. There was measurement of body composition, blood pressure, and biochemical parameters. In order to determine the metabolic syndrome diagnosis, criteria by the International Diabetes Federation were applied. There was bivariate analysis among those who presented diagnostic criteria for SM and those who did not, using the Mann Whitney’s U test for hypothesis contrast.Results: the mean age of the sample studied was 59.7% (SD: 11.5 years). Most participants were female (65.3%) and with a middle socioeconomic level (75.5%). The prevalence of metabolic syndrome was 40%, and hyperglycaemia was the most frequent alteration (93.3%). The majority of patients with MS showed statistically significant overweight and obesity (p< 0.05), as well as higher figures of body mass index, waist circumference, total cholesterol, triglycerides, glucose, atherogenic indexes and blood pressure.Conclusions: patients with T2D showed a high prevalence of MS. In patients with MS, hyperglycaemia was the most frequent alteration, followed by central obesity measured by waist circumference; and according to their BMI, the majority presented overweight and obesity. The mean triglycerides, blood pressure and atherogenic indexes of these patients were higher vs. those who did not meet diagnostic criteria for MS. (AU)

Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome

Background: The aim of this study was to investigate the common gene signatures and potential molecular mechanisms of bladder urothelial carcinoma (BLCA) and metabolic syndrome (MS). Methods: Transcriptome data for BLCA and MS were obtained from the Gene Expression Omnibus (GEO) database. Weighted gene co-expression network analysis (WGCNA) was utilized to identify co-expression networks associated with BLCA and MS, and five hub genes were further screened and validated using logistic least absolute shrinkage and selection operator (LASSO) regression models and receiver operating characteristic (ROC) curve, and external dataset for validation. The relationship between the hub genes and the clinicopathological characteristics and prognosis of BLCA patients was explored in the GEO and The Cancer Genome Atlas (TCGA)-BLCA cohorts, respectively. Differences in the immune microenvironment of BLCA and MS were analyzed using the database CIBERSORT and the R package “ssGSEA”, and the correlation between hub genes and tumor microenvironment, immune score and targeted drugs was analyzed with the help of the TCGA-BLCA cohort. Finally, BLCA single-cell RNA (scRNA) data were used to analyze the expression levels of the hub genes in various cell types of BLCA and molecular mechanisms. Results: Five hub genes were screened by WGCNA and LASSO regression analysis, namely AP2-associated protein kinase 1 (AAK1), ATP-binding cassette subfamily F member 2 (ABCF2), Mitochondrial ribosomal protein L42 (MRPL42), La-related protein 3 (SSB) and TATA-box binding protein-associated factor 10 (TAF10). Analyzed in the GEO and TCGA-BLCA cohorts, we found that the hub genes (TAF10 and ABCF2) were closely associated with the clinicopathological characteristics and prognosis of BLCA patients (AU)

Visceral adiposity indicators and anthropometric indices as screening tools of metabolic syndrome among chinese athletic patients

Aim: More alarming is the increase in the metabolic syndrome (MetS) prevalence in athletic patients suffering adult growth hormone deficiency (AGHD). Chinese visceral adipose index (CVAI) serves for measuring visceral adiposity as well as predicting Chinese people’s MetS, while studies have not confirmed its predictive ability for AGHD athletic patients. The study aims at proving such predictive ability by directly comparing the screening abilities exhibited by CVAI, VAI, LAP, WHR, WHtR and WC for identifying MetS of AGHD athletic patients in China. Materials and methods: The study involved 113 AGHD athletic patients together with 113 healthy controls, calculating the CVAI, LAP, VAI, BMI, WHtR, WHR, and HOMA-IR. The definition of MetS followed the Joint Interim Statement criteria. The ROC assisted in comparing the AUC regarding each index, obtaining their cut-off points for the prediction of MetS. Results: The WC, WHR, WHtR, VAI, LAP and CVAI were in a higher level in AGHD patients. AGHD patients had a MetS prevalence of 41.3 %. AGHD athletic patients suffering MetS exhibited remarkably larger WC, WHR, WHtR, VAI, LAP, CVAI but lower IGF-1, relative to those without MetS. The CVAI was taken into account to divide AGHD patients to four quartiles. With the increase in CVAI, HDL-C, IGF-1 declined, while other related indicators were on the rise. Pearson analysis revealed the obvious association between CVAI, VAI and LAP with MetS, regardless of gender and age. According to the ROC curve of VAI and the anthropometric indicators (ATI) diagnosing metabolic syndrome, CVAI presented the maximum AUC value (85.80 and 84.45 for males and females, respectively) for AGHD patients (AU)

Metabolic Syndrome is Associated with Prostate Cancer Diagnosed on Biopsy but not the Gleason Score and the Number of Cancer-Positive Cores: A Prospective Controlled Study

Objective: We aimed to investigate the association between metabolic syndrome (MetS) and prostate cancer (PCa) in patients undergoing prostate biopsy. Materials and Methods: Between January 2018 and December 2022, MetS was investigated according to Adult Treatment Panel III (ATP III) criteria in men who underwent prostate biopsy with transrectal ultrasound (TRUS). Clinicopathological factors such as, digital rectal examination (DRE), prostate-specific antigen (PSA), prostate volume, waist circumference, body mass index (BMI), age, blood pressure, testosterone, lipid profiles, fasting blood glucose level, C-reactive protein (CRP) and MetS were analyzed. Results: A total of 908 men underwent biopsies, of which 492 (51.5%) had MetS according to ATP III criteria. The number of patients diagnosed with PCa in biopsy was 270 (29.7%). PCa cases were significantly older, with a lower prostate volume and a higher PSA value and higher blood pressure compared to patients without PCa (p < 0.001). 146 of 416 (35.0%) patients with MetS had PCa while 124 of 492 (25.2%) patients without MetS had PCa (p < 0.001). Out of 270 patients with PCa, 174 (64.4%) had Gleason score <7 and 96 (35.6%) had Gleason score ≥7. In patients with a Gleason score ≥7, PSA, DRE(+) and core positive number were significantly higher compared to patients with Gleason score <7, while glycemia and high-density lipoprotein (HDL) cholesterol levels were significantly lower (p < 0.001). Multivariate analysis showed that age, PSA, positive DRE, prostate volume (p < 0.001), diastolic blood pressure, CRP and MetS were the only independent parameters associated with a higher risk of cancer on biopsy (p < 0.05). Conclusions: Our findings show that MetS is associated with PCa diagnosed on biopsy but not with the Gleason score and the number of cancer-positive cores. However, these results should be confirmed by larger, multicenter and prospective studies (AU)

Effect of MetioNac® in patients with metabolic syndrome who are at risk of metabolic dysfunction associated fatty liver disease: a randomized controlled trial / Efecto de MetioNac® en pacientes con síndrome metabólico que están en riesgo de padecer enfermedad de hígado graso asociado a disfunción metabólica: un estudio controlado aleatorizado

Introduction: metabolic syndrome comprises a combination of diabetes, high blood pressure, and obesity, and metabolic associated fatty liver disease (MAFLD) is associated with it. Objective: to evaluate the effect of supplementation with S-adenosyl-L-methionine + N-acetylcysteine + thioctic acid + vitamin B6 (MetioNac®) for 3 months on lipidic and biochemical parameters in subjects with metabolic syndrome and at risk of MAFLD. The reduction in body weight and the oxidative stress markers malondialdehyde (MDA) and superoxide dismutase (SOD) were also evaluated. Methods: patients with metabolic syndrome, at risk of MAFLD (FIB-4 < 1.30), and with an indication for weight reduction were recruited (n = 15). Control group followed a semipersonalized Mediterranean diet (MD) for weight reduction, according to the recommendations of the Spanish Society for the Study of Obesity (SEEDO). Experimental group, in addition to the MD, took three capsules of MetioNac® supplement per day. Results: compared with the control group, subjects taking MetioNac® showed significant (p < 0.05) reductions in the levels of TG and VLDL-c, as well as in total cholesterol, LDL-c, and glucose levels. They also showed increased levels of HDL-c. Levels of AST and ALT decreased after the intervention with MetioNac®, but this decrease did not reach statistical significance. Weight loss was observed in both groups. Conclusion: supplementation with MetioNac® may be protective against hyperlipidemia, insulin resistance, and overweight among metabolic syndrome patients. Further studies on this issue are needed in a larger population.(AU)

Introducción: el síndrome metabólico se define como una combinación de diabetes, hipertensión arterial y obesidad, que se asocia con laenfermedad del hígado graso asociada a disfunción metabólica.Objetivo: evaluar el efecto de la suplementación con S-adenosil-L-metionina + N-acetilcisteína + ácido tióctico + vitamina B6 (MetioNac®)durante 3 meses sobre parámetros lipídicos y bioquímicos en sujetos con síndrome metabólico y en riesgo de enfermedad del hígado grasoasociada a disfunción metabólica. También se evaluaron la reducción del peso corporal y los marcadores de estrés oxidativo malondialdehído(MDA) y superóxido dismutasa (SOD).Métodos: se reclutaron pacientes con síndrome metabólico, riesgo de enfermedad del hígado graso asociada a disfunción metabólica (FIB-4 < 1,30) y con indicación de reducción de peso (n = 15). El grupo control siguió una dieta mediterránea (DM) semipersonalizada para la reducciónde peso, de acuerdo con las recomendaciones de la Sociedad Española para el Estudio de la Obesidad (SEEDO). El grupo intervención, ademásde la DM, tomó tres cápsulas diarias de MetioNac®.Resultados: en comparación con el grupo de control, los sujetos que tomaron MetioNac® mostraron reducciones significativas (p < 0.05) en losniveles de TG y VLDL-c, así como en los niveles de colesterol total, LDL-c y glucosa. También mostraron niveles elevados de HDL-c. Los nivelesde AST y ALT disminuyeron después de la intervención con MetioNac®, pero esta disminución no fue estadísticamente significativa. También seobservó una pérdida de peso en ambos grupos.Conclusión: la suplementación con MetioNac® puede proteger contra la hiperlipidemia, la insulinorresistencia y el sobrepeso en pacientes consíndrome metabólico. Sin embargo, es necesario realizar más estudios y seleccionar un mayor número de participantes.(AU)

Schizophrenia is associated with severe consequences / Asociación de la esquizofrenia con consecuencias graves

Schizophrenia is an illness that affects millions of individuals. It is typically accompanied by positive, negative and cognitive symptoms. These symptoms are typically associated with the onset and progression of schizophrenia. However, aside from these known symptoms, there are consequences of having schizophrenia. In particular, metabolic syndrome, early death and suicide, diseases, lowered pain perception, sexual dysfunction, aggressive behavior/victimization, stigma, and cognitive deficit are all consequences of having schizophrenia. In this paper, we review the various consequences of having schizophrenia. These consequences should be monitored for, much like the typical symptoms, but are usually omitted from treatment. (AU)

La esquizofrenia es una enfermedad que afecta a millones de individuos, y que normalmente se acompaña de síntomas positivos, negativos y cognitivos. Dichos síntomas están normalmente asociados al inicio y progresión de la esquizofrenia. Sin embargo, aparte de estos síntomas conocidos, existen consecuencias de padecer esquizofrenia. En particular, el síndrome metabólico, la muerte prematura y el suicidio, las enfermedades, la disminución de la percepción del dolor, la disfunción sexual, el comportamiento agresivo/victimización, el estigma, y el déficit cognitivo son consecuencias de padecer esquizofrenia. En este documento, revisamos las diversas consecuencias del padecimiento de esquizofrenia. Deberán supervisarse dichas consecuencias, al igual que los síntomas típicos, aunque normalmente se omiten del tratamiento de la enfermedad. (AU)

Estimación predictiva en población laboral del Índice de adiposidad visceral (VAI) y adiposidad disfuncional (DAI) en síndrome metabólico / Predictive estimation of the Visceral Adiposity Index (VAI) and Dysfunctional Adiposity Index (DAI) for metabolic syndrome in a working population

Introducción: Evaluar el síndrome metabólico utilizando tres métodos propuestos por ins-tituciones internacionales de referencia, y los índices de adiposidad visceral (VAI) y adiposi-dad disfuncional (DAI), en la predicción y estimación de la prevalencia en población laboral.Métodos: Estudio transversal en trabajadores de distintas comunidades autónomas espa-ñolas a los que se les realizó un examen de salud entre enero 2019 y septiembre 2021 por cuatro servicios de prevención de riesgos laborales. Se evaluó el síndrome metabólico con criterios del National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP-III), International Diabetes Federation (IDF) y Joint Interin Statement (JIS). Se calcularon los valores de VAI y DAI mediante sus fórmulas específicas y su capacidad predictiva mediante curvas ROC. Se utilizó el programa SPSS 27.0, considerando significación estadística p< 0,05.Resultados: Se incluyeron 418 343 trabajadores, la mayoría hombres (58,8%), de edad me-dia entre 30 y 49 años (58,0%), clase social III, tipo de trabajo manual (75,9%) y no fumado-res (66,9%). La prevalencia de síndrome metabólico muestra diferencias según el criterio utilizado, siendo superior en hombres con IDF y JIS, y en mujeres con ATPIII. Para las tres definiciones de síndrome metabólico, los valores del área bajo la curva fueron > 0,8 (>80%). El VAI más elevado se obtuvo con JIS, y el DAI más alto con ATPIII. El índice de mayor con-fianza fue para ATPIII y JIS.Conclusiones: Los índices de adiposidad VAI y DAI muestran una elevada capacidad pre-dictiva del síndrome metabólico con los tres criterios utilizados y pueden ser de utilidad preventiva en salud laboral (AU)

Objective: To evaluate metabolic syndrome using three methods proposed by recog-nizedinternational institutions, and the visceral adiposity (VAI) and dysfunctional adiposity (DAI) indices for prediction and prevalence estimation in working populations.Methods: Cross-sectional study in workers from different Spanish autonomous communi-ties who underwent a health examination between January 2019 and September 2021 at four occupational risk prevention services. Metabolic syndrome was evaluated according to criteria from the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP-III), the International Diabetes Federation (IDF) and the Joint Interim Statement (JIS). VAI and DAI values were calculated using their specific formulas and their predictive ca-pacity was measured using ROC curves. The SPSS 27.0 program was used, with statistical significance level set at p< 0.05.Results: 418 343 workers were included, mostly men (58.8%), average age between 30 and 49 years (58.0%), social class III, mostly manual workers (75.9%) and nonsmokers (66.9%). The prevalence of metabolic syndrome differed depending on the criteria used, being high-er in men with IDF and JIS, and in women with ATPIII. For the three definitions of metabolic syndrome, the values of the area under the curve were > 0.8 (>80%). The highest VAI was obtained with the JIS, and the highest DAI with the ATPIII. The highest confidence index was for ATPIII and JIS. Conclusions: The VAI and ICD adiposity indices show high predictive capacity in metabolic syndrome with all three criteria used and can be useful for prevention activities in occupa-tional health (AU)

Metabolic Syndrome Predicts Uric Acid Stones in the Upper Urinary Tract: Development and Validation of a Nomogram Model

Background: Accurately identifying uric acid stones is pivotal in determining the appropriate treatment strategy for patients. This study aimed to design an innovative nomogram to predict the occurrence of uric acid stones in the upper urinary tract. Methods: This retrospective study examined 680 patients with urinary stones from October 2019 to September 2022. Risk factors were identified through univariate and multivariate logistic regression, leading to the development of a nomogram. This model’s validity was then assessed internally using receiver operating characteristic (ROC) curves, the area under the curve (AUC), calibration curves, and decision curve analysis (DCA). Results: Our findings revealed that metabolic syndrome (odds ratio (OR) = 4.347, 95% confidence interval (CI) 1.306–14.466, p = 0.017), serum urea levels (OR = 1.004, 95% CI 1.143–2.002, p = 0.004), urinary pH (OR = 0.185, 95% CI 0.059–0.583, p = 0.004), urinary potassium (OR = 0.926, 95% CI 0.875–0.981, p = 0.009), and urinary calcium (OR = 0.693, 95% CI 0.492–0.977, p = 0.037) are independent factors for upper urinary tract uric acid stones. Utilizing the five variables, we developed a predictive nomogram. The AUC of the training cohort and the validation cohort were 0.917 (95% CI 0.871–0.963) and 0.914 (95% CI 0.850–0.978), respectively. Calibration curves indicated strong consistency in both cohorts, and the DCA revealed the model’s clinical utility. Conclusions: We devised a reliable and user-friendly nomogram to predict uric acid stones in the upper urinary tract. It is based on metabolic syndrome, serum biochemical markers, and 24-hour urinary parameters. Key determinants include metabolic syndrome, serum urea, urinary pH, urinary potassium and urinary calcium (AU)